Effect of Baseline Resistance-Associated Variants on SVR with the 3D Regimen with and without RBV in GT1a and GT1b-Infected Patients
Christoph Sarrazin(St. Josefs Hospital), Christine A. Collins(AbbVie (United States)), Lino Rodrigues(AbbVie (United States)), Rakesh Tripathi(AbbVie (United States)), Gretja Schnell(University of North Carolina at Chapel Hill), Preethi Krishnan(Indiana University School of Medicine), Yan Luo(AbbVie (United States)), Mark Sulkowski(Johns Hopkins University), Daniel E. Cohen(AbbVie (United States)), Roger Trinh(AbbVie (United States)), Nancy S. Shulman(AbbVie (United States)), Yan Xie(Chinese Academy of Medical Sciences & Peking Union Medical College)
Cited by 2
Related Papers
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection†‡
|Hepatology|2006|4.8k
Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
|New England Journal of Medicine|2013|1.1k
ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis
|New England Journal of Medicine|2014|877
Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease
|Gastroenterology|2015|799
Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection
|Annals of Internal Medicine|2017|694